Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Oct 24, 2026 | CGS Administrators | Positron Emission Tomography (PET) Scan for Inflammation and InfectionLCD · CGS-L39521 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Cosmetic and Reconstructive SurgeryLCD · CGS-L39506 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Cosmetic and Reconstructive SurgeryLCD · CGS-L39506 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell OriginLCD · CGS-L39434 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell OriginLCD · CGS-L39434 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid ArthritisLCD · CGS-L39427 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid ArthritisLCD · CGS-L39427 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaLCD · CGS-L39389 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaLCD · CGS-L39389 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Sacroiliac Joint Injections and ProceduresLCD · CGS-L39383 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Sacroiliac Joint Injections and ProceduresLCD · CGS-L39383 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Prostate Cancer Detection with IsoPSA®LCD · CGS-L39284 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Prostate Cancer Detection with IsoPSA®LCD · CGS-L39284 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLCD · CGS-L39276 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLCD · CGS-L39276 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingLCD · CGS-L39038 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingLCD · CGS-L39038 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Platelet Rich Plasma Injections for Non-Wound InjectionsLCD · CGS-L39023 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Platelet Rich Plasma Injections for Non-Wound InjectionsLCD · CGS-L39023 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with CancerLCD · CGS-L39017 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with CancerLCD · CGS-L39017 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Epidural Steroid Injections for Pain ManagementLCD · CGS-L39015 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Epidural Steroid Injections for Pain ManagementLCD · CGS-L39015 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate CancerLCD · CGS-L38997 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate CancerLCD · CGS-L38997 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Electroretinography (ERG)LCD · CGS-L38992 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Electroretinography (ERG)LCD · CGS-L38992 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Off-label Use of Rituximab and Rituximab BiosimilarsLCD · CGS-L38920 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Off-label Use of Rituximab and Rituximab BiosimilarsLCD · CGS-L38920 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Minimal Residual Disease Testing for CancerLCD · CGS-L38822 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Minimal Residual Disease Testing for CancerLCD · CGS-L38822 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Colon Capsule Endoscopy (CCE)LCD · CGS-L38777 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Colon Capsule Endoscopy (CCE)LCD · CGS-L38777 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Facet Joint Interventions for Pain ManagementLCD · CGS-L38773 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Facet Joint Interventions for Pain ManagementLCD · CGS-L38773 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart DiseaseLCD · CGS-L38771 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart DiseaseLCD · CGS-L38771 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Computed Tomography Cerebral Perfusion Analysis (CTP)LCD · CGS-L38694 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Computed Tomography Cerebral Perfusion Analysis (CTP)LCD · CGS-L38694 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Implantable Continuous Glucose Monitors (I-CGM)LCD · CGS-L38662 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Implantable Continuous Glucose Monitors (I-CGM)LCD · CGS-L38662 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLCD · CGS-L38586 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLCD · CGS-L38586 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLCD · CGS-L38584 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsLCD · CGS-L38584 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Pharmacogenomics TestingLCD · CGS-L38394 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | MolDX: Pharmacogenomics TestingLCD · CGS-L38394 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)LCD · CGS-L38378 | Codes changed |
|---|
| Oct 24, 2026 | CGS Administrators | Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)LCD · CGS-L38378 | New policy |
|---|
| Oct 24, 2026 | CGS Administrators | Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLCD · CGS-L38307 | Codes changed |
|---|